Dear Editor, The SARS-CoV-2 infection can lead to severe acute respiratory distress syndrome (ARDS) with prolonged mechanical ventilation (MV). Patients with coronavirus disease 2019 (COVID-19) associated ARDS usually met the diagnosis criteria for sepsis-associated immunosuppression as acquired infections, primarily bacterial and fungal co-infections [1], are frequently encountered. Such secondary infections are associated with late mortality. Herpesviridae reactivation is common in non-immunocompromised patients with prolonged MV and could be responsible for increased mortality and longer duration of MV in ICU [2, 3]. Although the diagnosis of Herpesviridae pulmonary infection is challenging and not consensual in critically ill patients, therapeutic strategies are available to reduce morbidity and mortality [4]. As viral co-infections in these patients remain poorly investigated, we aimed to describe Herpesviridae pulmonary reactivations in patients with COVID-19 ARDS. Methods We reviewed all virology results for patients admitted to Rennes University Hospital (Rennes, France) for COVID-19 ARDS between March 3, 2020, and April 15, 2020. SARS-CoV-2 infection was confirmed by polymerase chain reaction (PCR). Patients mechanically ventilated longer than 7 days and who had negative PCR for herpes simplex virus (HSV) and cytomegalovirus (CMV) were included in the analysis. Herpes simplex virus and cytomegalovirus replication were measured by quantitative real-time PCR on tracheal aspirates twice a week for each patient. Herpesviridae reactivation was defined as two consecutive positive HSV or CMV PCR on tracheal aspirates. The Mann-Whitney rank sum test was used to compare non-parametric continuous variables, and qualitative data were compared using Fisher’s exact test. Statistical significance was defined as P 0.99 Women 11 (29) 5 (25) 6 (33) BMI 24 (24–31) 27 (23–27) 26.9 (24–29) 0.78 Current smoking 2 (5) 1 (5) 1 (5) 0.94 Coexisting conditions Any 19 (50) 10 (50) 9 (50) > 0.99 Diabetes 15 (40.5) 7 (35) 8 (44) 0.55 Cancer 3 (8) 2 (10) 1 (5) > 0.99 Clinical and biological baseline characteristics White blood cell count (109/L) 10.1 (3.4–13) 7.8 (6–10.4) 11.2 (7.3–13.2) 0.07 Lymphocyte count (109/L) 0.74 (0.59–1.04) 0.79 (0.53–1.06) 0.83 (0.7–1.23) 0.29 Ratio of PaO2 to FiO2 106 (95–170) 90 (69–142) 116 (90–147) 0.15 SAPS II score on day 1 42 (31–58) 39 (29–61) 42 (33–55) 0.65 SOFA score on day 1 3 (2–7) 7 (2–9) 3 (2–7) 0.81 Data are presented as median (IQR: interquartiles), n (%). P values comparing the Herpesviridae reactivation and no Herpesviridae reactivation groups are tested by the Mann-Whitney (continuous variables) or Fisher’s exact test (categorical variables) Abbreviations: BMI body mass index, ICU intensive care unit, PaO 2 arterial oxygen tension, FiO 2 fraction of inspired oxygen, SAPS II Simplified Acute Physiology Score, SOFA Sequential Organ Failure Assessment Patients with Herpesviridae reactivation had significantly longer duration of MV compared with patients without Herpesviridae reactivation. Table 2 shows outcomes of patients according to Herpesviridae reactivation status. Table 2 Treatments and clinical course of COVID-19 patients according to Herpesviridae status All patients (n = 38) No Herpesviridae reactivation (n = 20) Herpesviridae reactivation (n = 18) P value Antibiotics 38 (100) 20 (100) 18 (100) 0.99 Antiviral 32 (84) 16 (80) 16 (89) 0.66 Steroids 12 (32) 4 (20) 8 (44) 0.16 ECMO 3 (8) 1 (5) 2 (11) 0.49 Duration of NMB infusion 6 (3–11) 5 (3–8) 6 (3–11) 0.73 Renal replacement therapy 9 (24) 5 (25) 4 (22) 0.99 Prone positioning ventilation 21 (55) 11 (52) 10 (56) 0.24 Duration of mechanical ventilation 18 (13–25) 9 (6–14) 23 (18–39) 0.0001 Ventilator-free days at day 28 8 (0–15) 14 (7–20) 2 (0–3) 0.0008 Ratio of PaO2 to FiO2 on day 7 193 (135–248) 212 (160–260) 178 (135–195) 0.04 Ratio of PaO2 to FiO2 on day 14 216 (174–308) 280 (222–401) 186 (114–233) 0.01 SOFA score on day 7 7 (5–11) 7 (5–10) 10 (6–11) 0.19 SOFA score on day 14 7 (2–10) 3 (1–10) 7 (2–10) 0.39 Bacterial VAP 9 (24) 3 (15) 6 (33) 0.18 ICU length of stay 23 (16–34) 16 (12–24) 29 (24–47) 0.0001 Death in ICU 4 (10.5) 2 (10) 2 (11) 0.99 Data are presented as median (IQR: interquartiles), n (%). P values comparing the Herpesviridae reactivation and no Herpesviridae reactivation groups are tested by the Mann-Whitney (continuous variables) or Fisher’s exact test (categorical variables) Abbreviations: ECMO extracorporeal membrane oxygenation, NMB neuromuscular blockade, PaO 2 arterial oxygen tension, FiO 2 fraction of inspired oxygen, SOFA Sequential Organ Failure Assessment, VAP ventilator-associated pneumonia, ICU intensive care unit Discussion Our findings suggest that Herpesviridae reactivations are frequent in patients with COVID-19 ARDS, with higher rates than those described in previous studies performed in critically ill patients [2, 3]. This result was expected since severe forms of COVID-19 ARDS are associated with biological and clinical markers of acquired immunosuppression such as lymphopenia [1]. This state of immunodeficiency probably plays a role in the occurrence of viral reactivations. Among the most frequent risk factors for CMV and HSV reactivation in the ICU patients, sepsis and prolonged MV have been described in several studies [5, 6]. COVID-19 patients develop typical clinical and biological manifestations of septic shock [1]. There is no clear evidence that Herpesviridae reactivations induce difficulties to wean patients from MV nor increase the length of stay in COVID-19 patients, and our sample size did not allow us to perform a multivariate analysis. Larger studies are needed to explore such association. However, previous observational studies [5, 6] showed that Herpesviridae detection in the lower respiratory tract is associated with poorer outcomes. Finally, our results suggest that SARS-CoV-2 infection could be a risk factor for Herpesviridae reactivation. Rapid identification of these co-infections seems warranted as it may impact the prognosis of infected patients. However, the direct consequences and the usefulness of antiviral treatments for these Herpesviridae infections remain factors that deserve to be investigated.
